Taspoglutide

From Self-sufficiency
Jump to: navigation, search
Taspoglutide
Clinical data
Routes of
administration		 subcutaneous
Pharmacokinetic data
Bioavailability N/A
Identifiers
CAS Number 275371-94-3
ATC code none
Chemical data
Formula C152H232N40O45
Molar mass 3339.75 g/mol[[Script error: No such module "String".]]
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Taspoglutide is a glucagon-like peptide-1 analog drug under investigation for treatment of type 2 diabetes being co-developed by Ipsen and Roche.[1] [2]

Two phase II trials reported it was effective and well tolerated[3].

Of the eight planned phase III clinical trials of weekly taspoglutide (4 against exenatide, sitagliptin, insulin glargine, and pioglitazone) at least five were active in 2009.[4] Preliminary results in early 2010 were favourable.[5] (At least one of the 8 planned phase III trials had not started recruiting by end 2009.[6])

As of September 2010, Roche had halted Phase III clinical trials due to a incidences of serious hypersensitivity reactions and gastrointestinal side effects.[7][8]

Chemistry

Taspoglutide is the peptide with the sequence H2N-His-2-methyl-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-2-methyl-Ala-Arg-CONH2

In other words, it is the 8-(2-methylalanine)-35-(2-methylalanine)-36-L-argininamide derivative of the amino acid sequence 7–36 of human glucagon-like peptide I.

See also

exenatide (Byetta)
liraglutide (Victoza)
albiglutide

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />
Insulin
Meglitinides/"glinides"
Exenatide · Liraglutide · Taspoglutide† · Albiglutide† · Lixisenatide
Analogs/other insulins
Other
Amylin analog
SGLT2 inhibitors
Other


45px This drug article relating to the gastrointestinal system is a stub. You can help ssf by expanding it.
  1. ↑ "Ipsen: Roche Moves Investigational Diabetes Drug, Taspoglutide, into Phase III Clinical Trials". June 2008. 
  2. ↑ "Roche Moves Investigational Diabetes Drug, Taspoglutide, Into Phase III Clinical Trials". June 2008. 
  3. ↑ Baggio; et al. (2008). "Glucagon-like Peptide-1 Analogs Other Than Exenatide". 
  4. ↑ "Ipsen's Partner Roche Announces That Taspoglutide Meets Its Primary Endpoint In The First Phase III Clinical Trial". Oct 2009. 
  5. ↑ "Roche Reports Positive Data from Five Phase III Trials of Type 2 Diabetes Therapy". Feb 2010. 
  6. ↑ "A Study to Compare Taspoglutide and Insulin Glargine in Insulin-Naïve Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin and Sulfonylurea Combination Therapy". 
  7. ↑ "Roche Halts Trials of Taspoglutide". 
  8. ↑ "Experimental Diabetes Drug Taspoglutide Late-Stage Trials Suspended". 
Retrieved from "http://ssf.f15ijp.com/wiki/index.php?title=Taspoglutide&oldid=23713"